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Graves’ disease is an autoimmune disease characterized by hyperthyroidism due 
to circulating autoantibodies. Graves’ disease was originally known as “exophthalmic 
goiter” but is now named after Sir Robert Graves, an Irish doctor who first described 
the condition in 1835. A number of conditions can cause hyperthyroidism, but Graves’ 
disease is the most common, affecting around 1 in 200 people. It most often affects 
women under the age of 40, but it is also found in men. It affects an estimated 2–3 
percent of the world’s population. Thyroid-stimulating immunoglobulin (TSIs) binds 
to and activates thyrotropin receptors, causing the thyroid gland to grow and the thy-
roid follicles to increase synthesis of thyroid hormone. The overproduction of thyroid 
hormones can have a variety of effects on the body causes exophthalmic goiter, graves 
ophthalmopathy, graves dermopathy etc.,. Thyroid profile including antithyroid 
antibodies, radioactive iodine uptake study, and thyroid scan are the main diagnostic 
investigations to rule out Graves’ disease. The major aim of the treatment is to inhibit 
the overproduction of thyroid hormones by targeting the thyroid gland, to reduce the 
symptoms, and prevention of complication is also major challenges.
Keywords: anti-thyroid drug, autoimmune thyroid disease, goiter,  
graves disease, graves ophthalmopathy, hyperthyroidism, thyroglobulin, 
thyroidectomy, thyrotropine receptor antibody, radioactive iodine
1. Introduction
Thyroid diseases are one of the most common endocrinopathies globally [1]. 
The thyroid gland is a small, butterfly-shaped endocrine gland located in the lower 
front of the neck synthesizes and secretes mainly two hormones i.e., T4 (Thyroxine) 
and T3 (Triiodothyronine) [2] into the blood and then carried to every tissues in 
the body. TSH stands for thyroid stimulating hormone, which is produced by the 
pituitary gland of the brain. This gland stimulates the thyroid to synthesize and 
release the thyroid hormones into the blood. Thyroid hormones act on almost all 
nucleated cells and are essential for normal growth and energy metabolism1. It also 
controls the body temperature, menstrual cycles, the functioning of the lungs, heart 
& muscle strength and ancillary vital organs [3]. When thyroid gland secretes either 
too much or too little of the thyroid hormones T4 and T3, it’s called a thyroid disease. 
There are several different types of thyroid disease, including hyperthyroidism, 
hypothyroidism, thyroid cancer, thyroiditis, and autoimmune thyroid disease.
Graves’ disease is an autoimmune disorder that leads to overactivity of the entire 
thyroid gland due to circulating autoantibodies. The synonyms of Grave’s disease 
are Basedow disease, exophthalmic goiter, Graves’ hyperthyroidism, Parry disease 
and toxic diffuse goiter [4]. Graves’ disease is the commonest cause of hyperthy-
roidism. Graves’ disease was originally known as exophthalmic goiter but now it 
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is named after Sir Robert Graves, an Irish physician, who described this form of 
hyperthyroidism in 1830s [5]. Autoimmune thyroid disease ranges from one end of 
Hashimoto’s hypothyroidism (HH) to another end of Graves’ hyperthyroidism (GH). 
Autoimmune diseases are characterized by the activity of autoreactive lymphocytes, 
which cause tissue or organ damage through the formation of antibodies that react 
against host tissues, or effector T cells, which are specific for endogenous self-pep-
tides [6]. Thyroid peroxidase (TPO) and thyroglobulin (Tg) are the major auto-
antigens in Hashimoto’s disease whereas in Graves’ disease TPO-Ab and Tg-Ab are 
also occur in 70% of patients with Graves’ disease [7], but The thyroid-stimulating 
hormone receptor (TSHR) is the major autoantigen in Graves’ disease. The antibody 
called thyrotropin receptor antibody (TRAb) and thyroid-stimulating immunoglob-
ulins (TSIs) bind to and activate thyrotropin receptors, causing the thyroid gland to 
grow and the thyroid follicles to increase synthesis of thyroid hormone.
Graves’ disease is not only affecting the thyroid and often affecting the skin and 
eyes named as Graves’ dermopathy, Graves’ orbitopathy and Graves’ ophthalmopa-
thy. The overproduction of thyroid hormones can have a variety of effects on the 
other body systems too. About 3 in every 4 people with an overactive thyroid gland 
have a condition called Graves’ disease [8]. Graves’ disease is considered to be an 
autoimmune disorder, but other causes may contribute to its development, includ-
ing genetic, environmental, and/or other factors. Graves’ disease usually affects 
people between ages 30 and 50, but can occur at any age [9]. The disease is seven to 
eight times more common in women than men [10].
2. Epidemiology
Graves’ disease occurs in almost any part of the world. Graves’ disease is the most 
common causes of spontaneous thyrotoxicosis and it represents 60–90% of all causes 
of thyrotoxicosis in different regions of the world and it is estimated to affect 2–3 
percent of the world’s population [4]. Graves’ disease is the most common cause of 
hyperthyroidism in the United States. The incidence of Graves’ disease in Olmstead 
County was found to be 30 cases per 100,000 annually [11]. The overall prevalence 
of hyperthyroidism in the United States is 1.2% with an incidence of 20/100,000 to 
50/100,000 in a study conducted in Olmstead County, Minnesota. The incidence 
of Graves’ disease was 24.8 cases per 100,000 with an adjusted female to male ratio 
of 3.9:1 [12, 13] but studies specifically on Graves’ disease are rare [14]. In Canada, 
Graves’ disease is the most common cause of hyperthyroidism affecting one in every 
100 people. It appears to becoming even more common. In the Wickham Study in 
the United Kingdom, the incidence of Graves’ disease was reported to be 100–200 
cases per 100,000 population per year which is significantly higher than previous 
estimates [15] and among women, it has been reported to be 80 cases 100,000 per 
year [16]. The age adjusted incidence of adult onset Graves’ disease in Sheffield, UK 
was 24.8 per 100,000 per year. It is more common in women than men and the most 
common in people with ages 20 to 50 years and the risk for Graves’ disease in women 
and men are 3% and 0.5%. The 12-year incidence of graves disease among women 
with 25 to 42 years was as high as 4.6/1000 as per Nurses’ Health Study II report. 
The ratio of 3.9:1 reported in this study is however in keeping with other studies in 
Iceland and Sweden that reported a gender ratio of 4:1 in hyperthyroidism in general 
[16]. In Sweden, the reported incidence of Graves’ disease (2003–2005) was 21.4 per 
100,000 per year with a Female:Male ratio of 5.6:1 [17].
The prevalence of maternal thyrotoxicosis is approximately 1 case per 500 persons, 
with maternal Graves’ disease being the most common etiology [10]. Graves’ disease is 




occurrence of postnatal thyrotoxicosis due to maternal antibodies, the incidence of 
spontaneous Graves’ disease in children before the age of ten is most unusual, but the 
incidence climbs with each decade until about age 60 [14–15, 19] . Pediatric Graves’ 
disease accounts for 10–15% of thyroid disorders in patients less than 18 years of 
age [20]. Graves’ disease is rare under the age of 5 years and has a peak incidence at 
10–15 years of age [21]. The incidence of Graves’ disease is believed to be between 
0.1 and 3 per 100,000 children [22] with a prevalence of 1 in 10,000 children in the 
United States [23]. A study found that out of 57 patients with the average age of the 
32.8 years, male:female ratio of 1:3.3, 52 (91%) had subacute thyroiditis as the cause of 
thyrotoxicosis while Graves’ disease was seen in 9% [24]. The Graves’ disease affecting 
all countries and races equally across the world and it occurs eight times more com-
mon in women than men between 30 to 60 years of age group [14, 15].
3. Causes
Graves’ disease is caused by a malfunction in the body’s disease-fighting immune 
system. The immune system usually produces antibodies against the target specific 
antigens such as bacteria, virus, or other foreign substance. In Graves’ disease, the 
immune system produces an antibody against the own cell of the thyroid gland. 
Normally, thyroid gland function is regulated by a hormone thyroid-releasing hor-
mone (TRH) which is secreted from the posterior lobe of the pituitary gland. The 
immune system produces antibodies called thyrotropin receptor antibody (TRAb) 
that trigger the TSH receptor, tricking and dominance over the normal function of 
the thyroid gland and also causing an oversecretion of thyroid hormones. However 
the exact cause for Graves’ disease is not well understood. Despite there are risk 
factors like a combination of genetic and environmental factors which triggered the 
immune system against the thyroid.
4. Risk factors
Although anyone can develop Graves’ disease, many factors (Table 1) can 
increase the risk of disease, including:
Genetic Environmental Agents




• Other autoimmune disorders
 ○ Type 1 diabetes
 ○ Rheumatoid arthritis
 ○ Pernicious anemia
 ○ Lupus erthymatosus
 ○ Addison’s disease
 ○ Vitiligo




• Pregnancy and the Postpartum Period
• Medication: (amiodarone,










Family history of Graves’ disease is a known risk factor; there is likely a gene 
or genes that can make a person more susceptible to the disorder. 70%–80% of 
susceptibility to autoimmune thyroid disease is based on genetics; individuals 
with a personal history of autoimmune disease or family history of autoimmune 
thyroid disease are the most susceptible. The specific genes involved include 
human leukocyte antigen-DR3, cytotoxic T lymphocyte-associated factor 4, CD40, 
protein tyrosine phosphotase-22 gene, thyroglobulin (Tg), and TSH receptor 
[25]. Graves’ disease include genes encoding thyroglobulin, thyrotropin receptor, 
HLA-DRβ-Arg74, the protein tyrosine phosphatase nonreceptor type 22 (PTPN22), 
and proteins involved in T cell signaling [26–28]. HLA-DRB1 and HLA-DQB1 also 
appear to be associated with Graves’ disease susceptibility. Cytotoxic T lymphocyte-
associated molecule-4 (CTLA4) is a major thyroid autoantibody susceptibility gene, 
[29, 30] and it is a negative regulator of T-cell activation and may play an important 
role in the pathogenesis of Graves’ disease. Heredity increases genetic susceptibility 
to environmental triggers.
4.1.1 Race
The loci associated with autoimmune thyroid diseases are AITD1, CTLA4, 
GD1, GD2, GD3, HT1, and HT2 among white race and also different loci have been 
linked in persons of other races. The more susceptible to occur autoimmune thyroid 
disease is influenced by gene in human leukocyte antigen region on chromosome 6 
and in CTLA4 on band 2q33. It is associated with specific HLA haplotypes and vary 
with ethnicity [10].
4.1.2 Gender
Women are much more likely to develop Graves’ disease than are men. Women 
develop it seven to eight times more frequently than men [10] and are due to the 
production of special proteins (called antibodies) that attack the thyroid gland. 
The ratio of developing Graves’ hyperthyroidism between women and men is 
7:1 and is often mediated with either more estrogen or less testosterone and also 
observed that moderate amounts of estrogen enhance immunologic reactivity 
[31–33]. However, the X-chromosome is the source of the increased susceptibil-
ity rather than sex steroid since the susceptibility continues after the menopause 
and X-chromosome inactivation has been linked with autoimmune thyroid 
disease [34].
4.1.3 Age
Typically, Graves’ disease is a disease of young women, but it may occur in 
persons of any age. Graves’ disease is usually occur in people between ages 30 and 
50 years but can occur at any age. The typical age range is 20–40 years and the most 
affected women are aged 30–60 years [35].
4.1.4 Other autoimmune disorders
People with other autoimmune disorders are more likely to develop Graves’ 
disease than people without these disorders such as type 1 diabetes, rheumatoid 






The remaining 20%–30% contribution to the onset of autoimmune thyroid 
disease is thought to be due to environmental exposures or triggers. Interfere with 
thyroid function at multiple sites, including thyroid hormone synthesis, thyroid 
hormone metabolism and excretion, and thyroid hormone action [36–39]. Most of 
these agents may influence the pituitary and thyrotropin (TSH) secretion, or even 
be partial thyroid hormone receptor agonists. There are a number of exposures that 
have been identified and proposed, both from human and animal studies (11–14) 
[40–43]. These include infections, life stress, iodine intake, smoking, medications 
such as amiodarone and interferon, radiation, and environmental toxicants. The 
environmental parameters commonly reported as contributing factors are infec-
tious agents, iodine, drugs (amiodarone, Interferon-a (IFN-a), and CD52 MABs), 
tobacco, and stress [44].
4.2.1 Infection
Autoimmune thyroiditis can be induced in experimental animals by certain 
viral infections. Graves’ disease has been associated with a variety of infectious 
agents such as Yersinia enterocolitica and Borrelia burgdorferi. Homologies have 
been shown between proteins of these organisms and thyroid autoantigens [45, 46]. 
Thyroid autoimmune disease is associated with infections in the thyroid gland 
itself such as subacute thyroiditis, congenital rubella etc., and could initiate class II 
molecule expression. When Hepatitis C infection is treated with interferon therapy 
is a well-recognized precipitator of autoimmune thyroid disease, although less com-
monly a Graves’ disease develops rather than thyroiditis [47].
4.2.2 Stress
Both physical and emotional stressful life events and illness may act as a trigger 
for the onset of Graves’ disease among people who have genes that increase their risk. 
A review of the literature including seven case–control studies has highlighted the 
preexistence of a ‘negative’ stressful event in patients with Graves’ disease [48–55]. 
In general, stress suppresses the immune function, possibly mediated by the actions 
of cortisol on immune cells. Stress-induced suppression may be followed by rebound 
immunologic hyperactivity which could precipitate autoimmune thyroid disease in 
genetically susceptible individuals. The major T helper cells involved in Graves’ disease 
is Th2 and more recently found that Th17 is favor for the production of the pathogenic 
antibody directed against the TSH receptor by B lymphocytes both in mice and 
humans. Stress hormones direct stimulate the Th2, and Th17 or Th1 and also induce 
IL4, IL6, and IL12 by dentritic cells. Stress causes immature DCs which induce apop-
tosis in Treg cells leads not to act like regulators of Th2 and Th17 effector cells. It has 
been found that patients with untreated Graves’ disease have low in Treg cells which is 
inversely correlated with serum concentration of TSH receptor antibodies [56].
4.2.3 Pregnancy and the postpartum period
Pregnancy or recent childbirth may increase the risk of the disorder, particularly 
among women who have genes that increase their risk. The immune suppression is 
associated with the onset of autoimmune diseases especially postpartum thyroiditis. 
Fetal microchimerism, fetal cells in maternal tissue has maternal immune response 
is recognized as a trigger for thyroid autoimmunity and development of postpar-
tum autoimmune thyroid disease [57]. During pregnancy severe Graves’ disease is 
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uncommon because hyperthyroidism is associated with increased pregnancy loss 
pregnancy loss and reduced fertility. Even if pregnancy occurs it can cause compli-
cation to mother as well fetus. Both B-cell and T-cell functions are declined during 
pregnancy, while Tregs increase dampening the disease [44, 58]. After delivery, 
the slow rebound from immunosuppression results in immune reactivity which 
contributes to the occurrence of postpartum thyroid disease, including recurrence 
or the new onset of Graves’ disease [59]. Around 30 percent of young women have 
a history of pregnancy in the 12 months before the onset of Graves’ disease [60], 
which shows that postpartum Graves’ disease is a surprisingly common condition 
and that pregnancy is a major risk factor for susceptible women.
4.2.4 Smoking
Cigarette smoke contains cyanide, which is metabolized to thiocyante, and 
can interfere with iodine concentration in the thyroid [37]. Cigarette Smoking has 
been associated with an increased production of T3 and thyroglobulin [61, 62], 
affect the thyroid hormone action [63], enhanced sympathetic nervous activity, 
or by affecting thyroid-directed autoimmune responses [49, 62, 64–66]. Cigarette 
smoking causes complex interactions with the immune system which may increase 
cytokines in orbit and thyroid causes Graves’ disease and also smokers who 
have Graves’ disease exacerbating risk of developing Graves’ ophthalmopathy 
[41, 67–68].
4.2.5 Dietary iodine
Iodine is essential for thyroid hormone production, although a number of 
regulatory factors allow a normal amount of thyroid hormone to be produced 
across a fairly wide range of iodine intake. Deficient iodine intake is well known 
to be associated with reduced thyroid hormone production. Excess iodine, how-
ever, can also have adverse effects depending on underlying thyroid function, as 
well as the extent and duration of iodine excess [69]. Patients with multinodular 
goiter and associated areas of autonomous, TSH-independent, thyroid hormone 
production can have excess thyroid hormone production in response to iodine, 
the Jod–Basedow effect. Increased immunogenicity of thyroglobulin, thyroid cell 
destruction, In response to iodine supplementation in areas of iodine deficiency, 
there is an increase in thyroid autoantibodies and in some cases autoimmune 
thyroid disease [42, 43, 70, 71]. The mechanism of stimulation of autoimmune 
thyroid disease in response to iodine supplementation is not established. Excess 
iodine intake is associated with highly iodinated Tg, which is thought to be more 
immunogenic than poorly iodinated Tg [42, 70].
4.2.6 Dietary selenium
Selenium interacts with immune response. Low selenium intake has been associ-
ated with an increase in thyroid autoantibodies, and selenium supplementation 
with a reduction in antibodies [41].
4.2.7 Medications
Medications associated with the onset of autoimmune thyroid disease include 
lithium, amiodarone, interferon α, interleukin 2, campath-1 h, and highly active 




autoimmunity, but accelerate the autoimmune process by interfering with thyroid 
function. It may stimulate the immune response at multiple sites. Medications differ 
in their mechanisms of stimulating thyroid autoimmunity, as well as the relative 
effect on promoting hypothyroidism or Graves’ disease [41].
4.2.8 Radiation Exposure
Radiation exposure especially medical radiation is one of the environmental 
exposures linked to effects on the thyroid which stimulate thyroid autoantibodies, 
increases thyroid antigens, inflammation. Autoimmune thyroid disease has been 
linked to therapeutic medical radiation [72–74]. Patients receiving 131I for thyroid 
disorder develop Graves’ disease later in their life and, sometimes, it can lead 
Graves’ ophthalmopathy [73]. Radiation therapy with 131I causes low level thyroid 
autoantibody positivity in a sensitive TSH receptor antibody measurement which 
was associated with the development of Graves’ disease [73].
4.2.9 Toxicants
The main sources of toxicants are industrial chemicals, pesticides and herbi-
cides, toxins in consumer goods, and heavy metals which may impair the thyroid 
function by recruiting antibodies to attack the thyroid. Most municipal water 
sources are now closely monitored for a range of toxicants, including those that 
affect the thyroid and well water also to be tested regularly for contaminants 
[75, 76].
5. Pathophysiology
Hypothalamic–pituitary-thyroid axis feedback mechanism is controlled 
the secretion of thyroid hormone by involving the interaction of stimulatory 
and inhibitory factors. Hypothalamus secretes Thyrotropin-releasing hormone 
(TRH) which stimulates the anterior lobe of pituitary gland to release Thyroid 
Stimulating Hormone (TSH). TSH binds with receptors on the thyroid gland 
leads to the release of thyroid hormones primarily T4 and to a lesser extent T3. 
Elevated levels of these hormones act on the hypothalamus to decrease TRH 
secretion and thus the synthesis of TSH and vice versa. Iodine requires for the 
synthesis of thyroid hormone. Dietary inorganic iodide is carried to the thyroid 
gland by iodide transporter. In the presence of thyroid peroxidase enzyme inor-
ganic iodide is converted to iodine and bound to thyroglobulin through a process 
called organification. This causes the formation of Monoiodotyrosine (MIT) and 
Diiodotyrosine (DIT) and coupled to form triiodothyronine (T3) and thyroxine 
(T4) and then stored in the thyroid’s follicular lumen with thyroglobulin. These 
preformed hormones which diffuse into the peripheral circulation form thyroid 
gland. In the peripheral circulation more than 99.9% of T4 and T3 are in inactive 
form. However, free T3 is 20–100 times more biologically active than free T4. 
Free T3 acts by binding to DNA-binding proteins in cell nuclei which regulate the 
transcription of various cellular proteins [77]. Any causes that alter the process 
leads to an increase in the peripheral circulation of unbound thyroid hormone can 
cause hyperthyroidism.
Thyroid Stimulating Hormone – Receptor (TSH-R) is a G-protein coupled 
receptor with seven transmembrane-spanning domains which primarily seen 
thyroid gland. It is also present in adipocytes, fibroblasts, bone cells and a variety 
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of additional sites [78, 79]. TSHR regulates thyroid growth and thyroid hormone 
production and secretion and TSH also acting via TSHR. Hyperthyroidism in 
Graves’ disease manifested by the production of autoantibodies against the 
TSHR. These autoantibodies mimic the effects of the hormone on thyroid cells 
thereby stimulating autonomous production of T3 and T4. The derangement 
of immune function also lead to the production of pathologic autoantibodies 
complex by involving B and T cells which enhance the several autoantigens in 
addition to TSH-R. In Graves’ disease, B and T lymphocyte-mediated autoimmu-
nity are known to be directed at 4 well-known thyroid antigens: thyroglobulin 
(Tg), thyroid peroxidase (TPO), sodium-iodide symporter and the thyrotropin 
receptor. Thyroid stimulating immunoglobulin binds with thyroid-stimulating 
hormone (TSH) receptor on the thyroid cell membrane and stimulates the 
action of the thyroid-stimulating hormone. It stimulates both, thyroid hormone 
synthesis and thyroid gland growth, causing hyperthyroidism and thyromegaly 
[3] The stimulating activity of thyrotropin receptor antibodies is found in 
the immunoglobulin G. Circulating autoantibodies against the thyrotropin 
receptor continuously stimulate the thyroid gland to increase the secretion of 
thyroid hormone and thyroglobulin that is mediated by 3,'5′-cyclic adenosine 
monophosphate which suppresses the secretion of pituitary thyrotropin. These 
autoanitbodies also stimulate iodine uptake, protein synthesis, and thyroid gland 
growth [80].
Intrathyroidal lymphocytic infiltration observed in initial histologic examination 
in autoimmune thyroid disease and can be correlated with thyroid antibodies titer. 
The thyroid cells express molecules due to being the source of autoantigens that 
mediate T cell adhesion and complement regulation such as Fas and cytokines which 
interact the immune system and also the proportion of CD4 lymphocytes is lower in 
the thyroid than in the peripheral blood. Besides being the source of autoantigens, 
the thyroid cells express molecules that mediate T cell adhesion and complement 
regulation (Fas and cytokines) that participate and interact with the immune 
system. In these patients, the proportion of CD4 lymphocytes is lower in the thyroid 
than in the peripheral blood. The increased Fas expression in intrathyroidal CD4 T 
lymphocytes causes CD4 lymphocyte reduction. The autoimmune thyroid disease 
susceptibility genes are CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 
[25, 81] which specific either Graves’ disease or Hashimoto thyroiditis. The two new 
susceptibility loci are RNASET2-FGFR1OP-CCR6 region at 6q27 and an intergenic 
region at 4p14 [82]. Positive Graves’ disease is strongly associated with thyroid-
stimulating hormone receptor and major histocompatibility complex variants with 
persistently thyroid stimulating hormone receptor autoantibodies. [83]
5.1 Graves’ thyroid gland
The thyroid gland is diffusely enlarged but not always. The pathological change 
of the thyroid gland is follicular hyperplasia, intracellular colloid droplets, cell 
scalloping, a reduction in follicular colloid, and a patchy (multifocal) lymphocytic 
infiltration. The majority of intrathyroidal lymphocytes are T cells but plenty of B 
cells may be present. In some areas, thyroid epithelial cell size correlates with the 
intensity of the lymphocytic infiltrate, suggesting thyroid-cell stimulation by local 
B cells secreting stimulating TSHR-Ab [84].
5.2 Autoantibodies of thyroid
Thyroid autoantibodies, including TSHR-Abs secretes spontaneously from 




activated autoantibodies when decline in serum thyroid autoantibody concen-
trations after antithyroid drug treatment, after thyroidectomy, and late after 
radioactive iodine therapy.
5.3 TSH receptor and autoantibodies
Long-acting thyroid stimulator (LATS) was found among patients with Graves’ 
hyperthyroidism [86] and it is proved to be an immunoglobulin which inhibited the 
binding of radiolabeled thyroid stimulating hormone to thyroid membranes due to 
the presence of antibodies to the TSH receptor (TSHR-Ab) [87].
5.4 TSHR agonists and antagonists
The characteristics TSHR-Abs are stimulatory or inhibitory or neutral. In case 
of Hashimoto’s thyroiditis, block the binding and action of TSH and, therefore, can 
cause hypothyroidism. Whereas in Graves’ disease, TSHR-Abs has both stimulating 
and blocking thereby the clinical presentation may manifest depend upon a balance 
between these different antibodies. In third category, TSHR-Abs is of the neutral 
variety which may bind to the receptor but not influencing thyroid stimulating 
hormone binding. However, these antibodies may not be entirely neutral and can 
have cell signaling capability of untoward changes [88].
5.5 Similarities with autoimmune thyroiditis
• Lymphocytic infiltration of the thyroid and anti-Tg and anti-TPO antibod-
ies in the serum occur in both Graves’ disease and chronic autoimmune 
(Hashimoto’s) thyroiditis
• The genetic susceptibility of both disorders is HLA
• Areas of cellular apoptosis may be seen even in Graves’ thyroid glands [89, 90].
• The presence of antibodies that bind to the TSH receptor in both disorders and 
differ in biological activities
• Progression from Graves’ hyperthyroidism to chronic autoimmune thyroiditis 
and hypothyroidism is well-recognized [91] and vice versa also occurs [92]. 
Patients who have hypothyroidism one year, Graves’ hyperthyroidism another 
year, and again hypothyroidism later [93].
• In families of patients, some members may have chronic autoimmune thyroid-
itis and others may have Graves’ disease [94]
5.6 Immune mechanisms of Grave’s disease
The immune mechanisms involved in the pathogenesis of Graves’ hyperthy-
roidism are molecular mimicry (specificity crossover), thyroid-cell expression of 
human leukocyte-associated molecules (antigens), and bystander activation [95].
5.7 B cell in Graves’ disease
Monoclonal antibody to the CD 34 antigen on the surface of B cells has dem-
onstrated that changing the B cell repertoire can have profound influences on 
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Graves’ disease [40]. B cell also plays an important role in TSHR-Ab interaction with 
retro-orbital TSHRs which expressed on fibroblasts and adipocytes cause Graves 
Ophthalmology [95].
5.8 T cell in Graves’ disease
T cells are present in the immune repertoire react with appropriate peptides which 
are derived from thyroid autoantigens in Graves’ disease. Secretion of thyroid-specific 
autoantibodies from B cells is increase against the activated T cells. The thyroid-spe-
cific T cells in Graves’ disease primarily act as helper (CD4+ Th1) cells. However, based 
on the production of cytokines, subsets of T cells have been distinguished most easily
• CD4+ Th1 cells — Secrete interleukin-2, interferon gamma, and tumor necro-
sis factor-alpha which in turn activate cytotoxic cells and may induce thyroid 
cell apoptosis when CD4+ Th1 cells activated
• CD4+ Th2 cells — Secrete interleukin −4 and interleukin −5 and activate 
antibody production.
• CD4+ Th17 cells — Interleukin −17 is secreted under the influence of interleu-
kin −23 by the CD4+ Th17 cells which is a newly identified pro-inflammatory 
subset of cells [95].
6. Clinical manifestations
Graves’ disease is a syndrome which consists of hyperthyroidism, goiter, 
Graves’ orbitopathy, and occasionally a Graves’ dermopathy referred to as pretibial 
or localized myxedema (PTM). High amounts of T4, T3, or both can cause an 
excessively high metabolic rate. Signs and symptoms of Graves’ disease manifested 
due to the effect of hypermetabolism as well over stimulation of nervous system by 





• Enlargement of the thyroid gland (goiter)
• May be palpable thyroid nodules
• Thyroid bruits on auscultation
6.3 Cardiovascular system
• Rapid or irregular heartbeat (palpitations)
• Increased heart rate (Tachycardia)







6.5 Gastro intestinal system
• Diarrhea or increased Frequent bowel movements
6.6 Musculoskeletal
• Proximal muscle weakness
• Easy fatigability
• Back Pain
• Increased risk for fracture
6.7 Neuromuscular system
• A fine tremor of the hands or fingers
• Hyperactive deep tendon reflexes
6.8 Metabolic
• Weight loss, despite normal eating habits




• Change in menstrual cycles











• Thick, red skin usually on the shins or tops of the feet a condition called 
Graves’ dermopathy or Pretibial Myxedema (PTM)
6.12 Extremities
• Edema
• Thyroid Acropachy: is a rare manifestation with characteristic imaging 
 findings. Clinically, it presents as nail clubbing, swelling of digits and toes.
• Onycholysis: Separation of the nail plate starting at the distal free margin 
and progressing proximally usually starting at the tip and/or sides on the ring 







Bulging eyes (Graves’ ophthalmopathy) Graves’ ophthalmopathy also called 
Graves Orbitopathy, Graves Eye Disease, or Thyroid Eye Disease (TED), is an 
autoimmune inflammatory disorder of the orbit and periorbital tissues, character-
ized by upper eyelid retraction, lid lag, swelling, redness (erythema), conjunctivitis, 
and bulging eyes (exophthalmos) It is a problem that develops in people with an 
overactive thyroid caused by Graves’ disease which increase rate of peripheral blood 
mononuclear cell conversion into CD34+ fibrocytes. These cells may contribute 
to the pathophysiology of ophthalmopathy by accumulating in orbital tissues and 
producing inflammatory cytokines, including TNF-alpha and IL-6. although most 
cases of thyroid-associated orbitopathy do not result in visual loss, this condition 
can cause vision-threatening exposure keratopathy, troublesome diplopia, and 
compressive optic neuropathy.
6.14.1 Early symptom
• Feeling of irritation in the eyes
• Excessive tearing or dry eye
• Forward displacement of the eye






• Swelling of the eye
• Inability to move the eye
• Corneal ulceration
• Rarely, loss of vision
7. Complications
7.1 Goiter
An enlarged thyroid gland that has grown big enough to appear as a visible bulge 
on the neck caused by Graves’ disease is known as a diffuse thyrotoxic goiter. As 
thyroid enlarges bigger without treatment, goiter gets big enough to make difficulty 
in swallowing, causes coughing, and sleep disruption.
7.2 Thyroid storm
If Graves’ disease left untreated or treated inadequately, can cause a rare but life-
threatening complication called Thyroid Storm also known as thyrotoxic crisis or 
accelerated hyperthyroidism and requires immediate emergency care. The sudden 
and drastic raise in thyroid hormones causes fever, sweating, vomiting, diarrhea, 
delirium, severe weakness, seizures, irregular heartbeat, yellow skin and eyes (jaun-
dice), severe low blood pressure, and coma.
7.3 Heart disorders
Untreated, Graves’ disease can lead to heart rhythm disorders, changes in the 
structure and function of the heart muscles leads to inability of the heart to pump 
enough blood to the cells to meet the metabolic demand. Hyper secretion of thyroid 
hormone causes left ventricular thickening which may lead to heart failure and 
cardiac-related death. Thyrotoxicosis also has been associated with dilated cardio-
myopathy, [96] right sided heart failure with pulmonary hypertension, diastolic 
dysfunction and atrial fibrillation [97]. An irregular heartbeat that can lead to 
blood clots, stroke, heart failure, and other heart-related problems such as angina.
7.4 Brittle bones
Untreated hyperthyroidism increase in the rate of bone resorption can lead to 
weak, brittle bones (osteoporosis). Too much thyroid hormone interferes with 
body’s ability to incorporate calcium into bones. Patients with Graves’ disease have 
significantly increased in serum calcium and phosphate, plasma FGF-23 compared 
to healthy individuals and amongst FGF-23 is physiologically related to serum 
phosphate homeostasis in untreated Graves’ disease [98].
7.5 Maternal/fetal complications
Possible complications of Graves’ disease during pregnancy include miscarriage, 
preterm birth, fetal thyroid dysfunction, poor fetal growth, maternal heart failure 
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and preeclampsia. Preeclampsia is a maternal condition that results in high blood 
pressure and other serious signs and symptoms.
8. Assessment and diagnostic investigations
8.1 History collection
Analysis of medical and family history with associated sign and symptoms.
8.2 Physical examination
From head to toe examination and the findings are diffusely enlarged thyroid 
gland, thyrotoxic signs and symptoms. The unique findings to Graves’ disease 
such as Graves ophthalmopathy and dermopathy, Myxedematous changes of the 
skin (usually in the pretibial areas) are described as resembling an orange peel 
in color and texture, and Onycholysis can be seen usually in the fourth and fifth 
fingernails.
8.3 Blood investigations including thyroid profile
In case of Graves’ disease, abnormally high levels of T3 and T4, and a very low 
level of TSH seen as well elevated TSI and positive Thyroid peroxidase antibody
• Thyroid stimulating hormone (TSH)
• Thyroid hormone Triiodothyronine (T3)
• Free T3 or Free triiodothyronine (FT3)
• Thyroid hormone Thyroxine (T4)
• Antithyroid Antibodies: Thyroid peroxidase (TPO) antibody titers provide an 
evidence for Graves’ disease. More than 95% of patients have positive assays for 
TPO (thyroperoxidase or microsomal antigen), and about 50% have positive 
anti-thyroglobulin antibody assays.
• Thyroid-stimulating Immunoglobulin (TSI): It is measured from drawn blood 
and increase in the level of TSI antibodies reveals that the thyroid gland is more 
active and release excess amounts of thyroid hormone into the blood (Table 2).
Hormone Normal range
Thyroid stimulating hormone (TSH) 0.40–4.50 mIU/mL
Thyroxine (T4) 5.0–11.0 ug/dL
Free Thyroxine (T4) 0.9–1.7 ng/dL
Triiodothyronine (T3) 100–200 ng/dL
Free triiodothyronine (FT3) 2.3–4.1 pg./mL
Table 2. 




8.4 Radioactive iodine uptake (RAIU) study
A radioactive iodine uptake test and scan will measure the amount of iodine that 
thyroid gland absorbs and also determines if the entire or only part of the thyroid 
is overactive. If thyroid absorbs more iodine from blood stream which indicates 
Graves’ disease.
8.5 Thyroid scan
It shows how and where iodine is distributed in the thyroid. With Graves’ 
disease, the entire thyroid is involved, so the iodine shows up throughout the gland. 
It also may confirm hypoechogenicity or intense vascularity of Graves’ disease if a 
color Doppler flow exam is done.
8.6 Thyroid ultrasound
High-frequency sound waves to produce images of structures inside the thyroid 
gland. It’s most useful when radioactive iodine uptake study is contraindicated such 
as pregnant women, iodine hypersensitivity.
8.7 Imaging test
computed tomography (CT) scan or magnetic resonance imaging (MRI) scan 
is indicated for clear picture of thyroid gland when the clinical assessment is not 
clear. CT scan and MRI of the eye muscles and eye sockets (called orbital imaging) 
in order to define the exact impact of Graves’ disease on the eyes and to confirm the 
Graves ophthalmopathy.







• Bone mineral density Test
9. Treatment approaches
The main aims of the management of Graves’ disease are to inhibit the overpro-
duction of thyroid hormones by targeting thyroid gland and to alleviate the effect 









• Treating Graves’ ophthalmopathy
 ○ Corticosteroids.
 ○ Teprotumumab (Tepezza)
 ○ Prisms.
 ○ Orbital decompression surgery
 ○ Orbital radiotherapy
9.1 Radioactive iodine therapy
The most commonly used therapy for Graves’ disease is radioactive iodine 
(radioiodine) since the 1940s. It is still popular because it is non-invasive and highly 
effective on thyroid gland and has fewer side effects. Graves’ disease with a large 
thyroid gland, multiple symptoms of thyrotoxicosis, high levels of thyroxine, and 
high titers of TSI are indicated for radioactive iodine and women who are pregnant 
or breastfeeding are contraindicated for this therapy. Commonly used radioactive 
iodine is iodine-131 (I-131) and can be administered orally in the form of capsule 
or liquid. The dose is calculated based on the age, weight of the thyroid gland and 
radioiodine uptake and the usual dose ranges from 5–15 mCi. Iodine is essential for 
thyroid gland to produce hormones, the thyroid absorbs the radioiodine into the 
thyroid cells and the radiation destroys the hyperactive thyroid cells. This causes 
the thyroid gland to shrink, hormones to return normal and gradually alleviate 
the symptoms. It usually takes several weeks to several months. Follow up the 
patient and monitoring the thyroid profile is very important because it causes 
hypothyroidism.
9.2 Anti-thyroid medications
Antithyroid medications are one of the prominent methods to treat hyperthy-
roidism which interfere with the use of iodine by the thyroid to produce hormones. 
Commonly used antithyroid medicines are thionamides, such as propylthiouracil 
(PTU), and carbimazole (CBZ). Thionamides are actively transported into the 
thyroid gland where they inhibit both the organification of iodine to tyrosine 
residues in thyroglobulin and the coupling of iodotyrosines and hence reduce the 
synthesis of thyroid hormone [99, 100] and inhibit the function of thyroperoxi-
dase, reducing oxidation and the organification of iodide. Anti-thyroid drugs may 
be administered before or after radioiodine therapy as a supplemental treatment. 




liver disease is common in Propylthiouracil. However, propylthiouracil is the pre-
ferred anti-thyroid drug during the first trimester of pregnancy, as methimazole 
has a slight risk of birth defects and can continue the methimazole after the first 
trimester. Side effects of anti-thyroid drugs are allergic reactions such as skin rash, 
itching, lower resistance to infection due to decrease in white blood cells and rarely 
liver disease.
9.3 Beta blockers
Beta blockers do not have the direct effect on thyroid gland to reduce the hor-
mone secretion but can minimize the symptoms until the effect other treatments 
occur. Beta-blockers, such as propranolol and metoprolol, are often the first line of 
treatment. The action of beta blockers in hyperthyroidism is to antagonize beta-
receptor-mediated effects of catecholamines thereby reduce the heart rate, blood 
pressure, tremors, anxiety or irritability, heat intolerance, sweating, diarrhea, and 
muscle weakness. Beta blockers may trigger an asthma attack so aren’t often pre-
scribed for people with asthma and also complicate management of diabetes.
9.4 Thyroid surgery
Removal of part or total tissue of thyroid gland namely subtotal or total thy-
roidectomy is another option for the management of Graves’ disease. Surgery is less 
common and it is indicated when other treatment fails to manage. Pre-operatively, 
reduce the size of thyroid gland and bring to the euthyroidal state to reduce the risk 
of complications post-operatively. The complications of thyroidectomy include 
hypothyroidism, hypoparathyroidism, recurrent laryngeal nerve, hemorrhage. 
Patient undergone thyroidectomy has to receive the thyroid replacement hormone 
medication such as levothyroxine in remaining life.
9.5 Treating Graves’ ophthalmopathy
9.5.1 Over-the-counter artificial tears
Mild symptoms of Graves’ ophthalmopathy may be managed by using over-the-
counter artificial tears during the day and lubricating paraffin-based gels can be 
applied at night.
If symptoms are more severe:
9.5.2 Corticosteroids
Corticosteroids, such as prednisone, may lessen swelling behind eyeballs. 
Side effects may include fluid retention, weight gain, elevated blood sugar levels, 
increased blood pressure and mood swings.
9.5.3 Teprotumumab (Tepezza)
It’s given through an IV in the arm every three weeks and is given eight times. 
TEPEZZA targets and blocks IGF-1R and inhibits fibroblast activation via the 
IGF-1R/TSHR signaling complex at the source of the disease [101, 102] and 
decreases proptosis by [103–105] by reducing inflammation, preventing muscle and 
fat tissue remodeling, and preventing tissue expansion behind the eye. It can cause 




Prisms in eye glasses may correct the double vision as double vision is one of the 
effects of Graves’ disease.
9.5.5 Orbital decompression surgery
Removal of bone between eye socket (orbit) and sinuses, the air spaces next 
to the orbit. This decompression moves the eye back to their original position 
to release pressure on the optic nerve. This treatment is indicated if pressure 
on the optic nerve threatens the vision and treats the possible complication of 
double vision.
9.5.6 Orbital radiotherapy
It is common method of treatment using targeted X-rays to destroy the tissue 
behind the eyes but the underlying mechanism and benefits are not clear. It can be 
administered over the course of several days and is recommended if the Graves’ oph-
thalmopathy is worsening and not respond to corticosteroids or not tolerated well.
10. Patient education
10.1 Diet
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
stated that Graves’ disease can cause sensitivity to iodine. The symptoms of Graves’ 
disease may be worsening when consuming foods rich in iodine such as kelp and 
dulse or iodine supplements. The NIDDK warns to consult the physician before 
taking a multivitamin supplement or cough medicine, as these can contain iodine.
10.2 Exercise
Exercising can enhance the improvement in some symptoms during treatment. 
It controls the metabolism as there is a tendency to gain weight when the hyperthy-
roidism is corrected. Brittle bones also can occur with Graves’ disease, and weight-
bearing exercises can help maintain bone density.
10.3 Stress reduction
It may be helpful, as stress may trigger or worsen Graves’ disease. Yoga, medita-
tion, relaxation technique such as Listening to music, taking a warm bath or walk-
ing can help to reduce the stress and plan to follow in daily routine.
10.4 Optimal levels of iodine and selenium
Optimal iodine and selenium intake has been found to attenuate the toxic effects 
that heavy metals and perchlorate can have on the thyroid.
10.5 Avoid stimulants
Avoid consuming coffee, tea and quit the habit of smoking and alcohol as it 





Eyes are more vulnerable to ultraviolet rays and more sensitive to bright light 
when eyes protrude. Wearing sunglasses that wrap around the sides of head will 
also lessen the irritation of eyes from the wind.
10.7 Elevate the head end
Keep the head higher than the body lessens fluid accumulation in the head and 
may relieve the pressure on the eyes.
10.8 Cold compresses
Apply cold compress to the eyes to keep the eyes moisture which may 
soothe eyes.
11. Prognosis
Many patients with Graves’ disease remain well after the course of treatment 
with anti-thyroid drugs, radioactive iodine or surgery, but recurrence can happen at 
any time. Treatment approaches are very effective, but often results in abnormally 
low levels of thyroid hormones cause hypothyroidism. The Graves’ ophthalmology 
also tends to improve slowly with anti-thyroid drug treatment over years. However, 
some element of the staring appearance often remains.
12. Conclusion
This chapter briefed on epidemiology, causes and risk factors, pathophysiology, 
clinical manifestations, diagnostic investigations, management and complications 
of Graves’ disease. Graves’ disease is the autoimmune disorders of thyroid gland 
and the common cause of hyperthyroidism. It often poses complex challenges in 
diagnosing and managing the clients with Graves’ disease. Graves’ disease in some 
patients is curable within a limited time period with modern treatment but in some 
patients it is a chronic and relapsing. However untreated Graves’ disease causes the 
complications of thyroid storm, cardiac and ophthalmic complications and over 
treated Graves’ disease leads to hypothyroidism. Patient education is also plays an 
vital role in managing and preventing complications.
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